Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining Asn 101 to Asp 101 in CDR3-V H of rituximab is responsible for veltuzumab's lower off-rate and apparent improved potency in preclinical models that could translate into advantages in patients.
Introduction
Advances in medical treatments during the last ten years have witnessed the introduction of 9
antibodies for the therapy of diverse cancers. 1 Most of these new biological therapeutics are combined with conventional cytotoxic drugs, indicating that the antibodies require additional measures to improve their efficacy. 1 This is best exemplified with rituximab, the first-generation chimeric anti-CD20 monoclonal antibody (MAb) that was approved initially as a monotherapy for the treatment of NHL. 2 Based on this success, efforts are underway to introduce improved anti-CD20 antibodies. [3] [4] [5] [6] [7] [8] Most of these new MAbs are intended to reduce the murine components while enhancing
FcγR or complement-mediated functions. [8] [9] [10] One of the first second-generation MAbs developed to mitigate the infusion-related reactions experienced with rituximab is the hA20 MAb, 3 now termed veltuzumab, which has a shorter infusion time while indicating a higher complete response rate than has been reported for rituximab. 11, 12 Veltuzumab was constructed recombinantly on the framework regions (FRs) of epratuzumab, the humanized anti-CD22 MAb or hLL2, 13 but has identical variable kappa light-chain (V k ) complementarity-determining regions (CDRs), identical CDR1-V H and CDR2-V H , but a different CDR3-V H , compared to rituximab. Our initial characterization of veltuzumab 3 did not address whether these changes would result in different functions and therapeutic properties from those of rituximab. However, we postulated that, similar to the experience with epratuzumab, 14 it would be well tolerated during more rapid infusions than rituximab, which has been confirmed in monkeys, as shown herein, and in patients. 11, 12 We now report that veltuzumab has unique characteristics in terms of significantly improved complement-dependent cytotoxicity (CDC) in 1 of 3 cell lines, slower
For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From off-rates in all three lymphoma cell lines tested, and significantly improved therapeutic results in vivo in 3 different lymphoma models, compared to rituximab, and potent anti-B-cell activity in cynomolgus monkeys, thus corroborating the activity observed in patients at very low doses. Surprisingly, we have determined that these differences between veltuzumab and rituximab, at least with regard to off-rates, are related to a single amino acid change in CDR3-V H.
Methods

Antibodies
The development of veltuzumab has been described previously, 3 using the same human IgG donor FRs of epratuzumab. 13 Specifically, FR1, FR2, and FR3 of EU and FR4 of NEWM were selected for grafting the CDRs of V H , and the FRs of REI were selected for grafting the CDRs of V k . Key murine residues were retained in the FRs to maintain the binding specificity and affinity of veltuzumab for CD20 similar to those of the parental murine antibody (A20). The amino acid sequences of V H and V k are shown for A20, C2B8, and veltuzumab in Figures S1A and S1B.
The chimeric form of veltuzumab, cA20, was generated by grafting the V H and V k domains of A20 to the human constant regions; thus, cA20 differs from veltuzumab in the Table 1 compares the CDR3-V H of veltuzumab, cA20, D101N , rituximab, and 1F5, all of which have identical CDR1-V H and CDR2-V H sequences.
Cell lines
The murine hybridoma 1F5 and the human Burkitt lymphoma lines, Daudi, Raji, and Ramos, were purchased from ATCC. The non-Burkitt lymphoma cell lines were: SU-DHL-6 from Dr.
Alan Epstein (University of Southern California, Los Angeles, CA), and WSU-FSCCL from Dr.
Mitchell Smith (Fox Chase Cancer Center, Philadelphia, PA). The cells were grown as suspension cultures in DMEM (Life Technologies, Inc. Gaithersburg, MD), supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 μg/ml), and L-glutamine (2 mM).
Scatchard analyses
The maximum number of binding sites per cell and the apparent dissociation constants were determined by nonlinear regression analysis of the saturation binding data obtained with the radioiodinated samples and Raji cells, using Prism software (GraphPad Software Inc., San Diego, CA).
In-vitro cytotoxicity
The colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, first described by Mosmann, 15 was used to evaluate the in-vitro cytotoxicity by quantifying viable cells after treatments with anti-CD20 MAbs (5 μg/mL final concentration) for 4 days at 37°C in the absence or presence of goat-anti-human (GAH) IgG (20 μg/mL final concentration).
Ex-vivo depletion of B-and T-cells compared also to Daudi and Raji lymphoma cells
The effects of veltuzumab and rituximab on peripheral blood lymphocytes from healthy volunteers were evaluated ex-vivo using flow cytometry. Blood specimens were collected under 
Tolerability and toxicokinetics in cynomologus monkeys
An exploratory single-and repeated-dose study of i.v. and s.c. injections of veltuzumab was 
Evaluation of in vivo efficacy in mouse models
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Statistical differences in survival between treatment groups were analyzed using Kaplan-Meier plots (log-rank analysis of P values, which were considered significant at <.05) provided by Prism software.
Effects of depleting natural killer (NK) cells and neutrophils on therapy
Depletion of NK cells and neutrophils was conducted as described. 16 All animal studies were approved by the respective Institutional Animal Care and Use
Committees of the Center for Molecular Medicine and Immunology and Roswell Park Cancer
Institute, and performed in accordance with the AAALAC, USDA, and DHHS regulations.
Results
Cell binding analyses
The 
In vitro anti-proliferative activity
The ability of veltuzumab and rituximab to inhibit proliferation was examined on four lymphoma cell lines, SU-DHL-6, Daudi, Raji, and WSU-FSCCL, which differ in their expression levels of CD20, 3 using the MTT cell viability assay. While the sensitivity to both MAbs correlated with CD20 expression (SU-DHL-6 > Raji > Daudi > WSU-FSCCL), no significant differences in potency were observed between veltuzumab and rituximab within a cell line ( Figure S3 ).
Although crosslinking with GAH increased the efficacy of veltuzumab and rituximab on Raji and Daudi cells (both with intermediate levels of CD20 expression and sensitivity to killing by anti-CD20 MAbs), the addition of GAH did not further enhance the inhibition of proliferation of the highly sensitive SU-DHL-6 or the less sensitive WSU-FSCCL under the conditions tested.
B-and T-cell, and lymphoma depletion studies ex vivo
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The effects of veltuzumab and rituximab on human peripheral blood lymphocytes of healthy volunteers were assessed ex vivo using flow cytometry. Aliquots of whole blood were incubated with the MAbs for two days, followed by FACS analysis of B cells (CD19+) and T cells (CD3+).
Controls included no antibody and an isotype-matched, irrelevant antibody (labetuzumab).
Incubation of whole blood with veltuzumab at 5 and 1 μg/ml led to a statistically significant (P< .05) decrease of 26 -80% and 11 -61 %, respectively, in the number of B cells (Figure 2A ), but not T cells (data not shown). Similar results were obtained using rituximab (not shown). Because whole blood was used in the incubation mixtures, the decreases observed in the cell counts could be due to CDC, ADCC, as well as direct apoptotic signaling. 
CDC
With Daudi as the target cells for CDC, we observed consistently a lower value of EC 50 for veltuzumab (Table 2 ) when compared to rituximab. Further measurements addressing any effect of day-to-day variation as well as any differences in EC 50 patterns amongst the antibodies across different days indicated that the mean difference in EC 50 observed between rituximab and each of the three lots of veltuzumab was consistently statistically significant (P< .0001). However, no differences between veltuzumab and rituximab were observed with CDC results in the other two cell lines, Raji and Ramos.
ADCC
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With PBMCs as effector cells for ADCC, veltuzumab and rituximab produced similar extents of cell lysis (40-45%; P=.12), which were significantly higher (P< .0001) than labetuzumab (9.9%; data not shown).
PK studies in mice
While serum concentrations and clearance of veltuzumab were very similar between those animals injected i.p. and s.c. (Figure S4 ), several of their respective PK-parameters were significantly different (Tables S1 and S2 ). In terms of maximum serum concentrations (C max ) and the time to C max (T max ), there were no significant differences between the injection routes. 
Minimum effective dose of veltuzumab in follicular cell lymphoma xenografts
In disseminated follicular cell lymphoma, WSU-FSCCL, xenografts, mice were administered a single dose of veltuzumab (35, 3.5, 0.35, and 0.035 μg) i.p., 5 days after tumor inoculation. All four doses improved survival of the mice significantly (P<.0001) when compared to the saline controls ( Figure 3C ). The MST of mice administered the 35-μg dose (44.3 ± 4.9 days) was not significantly different from that of the 3.5-μg group (39.5 ± 4.6 days), but was significantly (P<.021) longer than that of the 0.35-and 0.035-μg (35 ng or 0.002 mg/kg) groups (40.5 ± 1.6 days and 33.3 ± 2.1 days, respectively). 
Comparative therapeutic effects of veltuzumab and rituximab
Effect of depleting NK cells and neutrophils on anti-lymphoma activity
We also examined the role of effector cells on veltuzumab's inhibition of Raji tumor growth in vivo ( Figure 4B ). In those animals depleted of NK cells and neutrophils, there was no difference between saline control and treated mice, both having the same MST (16.4 + 1.3 days). In the non-depleted group, veltuzumab-treated mice had a significantly improved MST over the saline controls (38.6 + 7.3 vs. 18.4 + 0.9 days; P<.0035).
Discussion
Due to our observations that rituximab combined with epratuzumab showed increased complete responses in NHL patients, with no increased side-effects over those resulting from monotherapy with rituximab, 14, [19] [20] [21] our original purpose was to develop a humanized anti-CD20 MAb that could be combined with epratuzumab, but would be more tolerable for rapid infusions due to
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From having the FRs of epratuzumab. The first characterization of veltuzumab reported similarities to rituximab in terms of epitope binding, affinity, ADCC, CDC, and cell growth inhibition in vitro. 3 Treating patients with NHL demonstrated a favorable tolerability and infusion profile, but also a high rate of complete responses (CR/CRu). The Phase I/II trial in 82 NHL patients is now being summarized for publication, but it has been reported already that the complete response rates for all doses tested (27% for all follicular lymphoma patients for doses between 80 and 750 mg/m 2 once-weekly x 4 weeks) 11, 12 exceed those reported for repeated use of rituximab at its conventional dose in comparable patients. 22 Ongoing studies also showed that single absolute doses of 80 mg of veltuzumab induced rapid B-cell depletion in patients with NHL or immune thrombocytopenic purpura, including reversal of thrombocytopenia in the latter patients (data on file, Immunomedics, Inc.). These findings prompted us to re-evaluate the functional properties of veltuzumab, also in comparison to rituximab, which is the subject of this article. .002 mg/kg). In these mouse studies, a dose-response was observed, but no significant difference between the i.v. or s.c. routes was noted.
In studies involving 3 lymphoma models in SCID mice, comparisons of low and high, single or multiple, doses showed a significantly increased survival time after veltuzumab compared to rituximab treatment, as conducted in two different laboratories. However, this was not consistent with ex-vivo cell studies showing equal potency of veltuzumab and rituximab in
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killing human B cells and either Daudi or Raji lymphoma cells, but it is interesting that both antibodies were more effective against the tumor cells than the normal human B cells, suggesting that there may be a higher density of CD20 on these lymphoma cells.
Although different anti-CD20 MAbs have shown some variations in functional properties and epitope specificities, mediating different CDC and cell-killing effects, 23 virtually all recognize the large, extracellular loop and partially or completely crossblock each other, [24] [25] [26] except ofatumumab, which is reported to bind to a novel epitope of CD20. 27 Veltuzumab crossblocks binding by rituximab, 3 suggesting either the same epitope is recognized by both
MAbs or binding to an adjacent epitope could result in steric hindrance.
In this study, the binding and dissociation parameters of veltuzumab and rituximab were Daudi being significantly more than rituximab or D101N is also intriguing, since the Fc portion of veltuzumab is derived from that of epratuzumab, which fails to show CDC functions. 27 This suggests that rapid internalization of epratuzumab may prevent it from residing on the cell surface long enough to form membrane attack complexes needed for CDC. Our results also suggest that the off-rate difference between veltuzumab and rituximab is not related to the enhanced CDC observed in Daudi cells, as first postulated for ofatumumab, 4 since this difference was not observed for CDC in two other cell lines (Raji and Ramos) that also showed a significantly slower off-rate with veltuzumab compared to rituximab. Although these findings with veltuzumab involve evidently a different targeted epitope of CD20 than ofatumumab, 28 we
are not convinced that such off-rate changes are due to the position of the epitope, as postulated by these authors. Nevertheless, we agree with Teeling et al. 4 that such off-rate changes, as also described herein, may explain an antibody functioning at lower concentrations than other MAbs, such as we have found with veltuzumab, but whether CDC plays a role remains speculative.
It is doubtful that these differences are related to veltuzumab having the FRs of epratuzumab. The V H and V K chains of cA20 differ from those of rituximab in six positions, but except for the 101-residue in CDR3-V H , the remaining five residues (two in FR4-V H and three in FR1-V K ) are unlikely to be responsible for the differential off-rates. Du et al. reported a weaker interaction of the CDRs of another anti-CD20 MAb, c2H7, compared to rituximab, suggesting that the amino acid residues of 2H7 at the equivalent positions in CDR3-V H have more bulky side chains, resulting in a wider pocket to accommodate the CD20 peptide. 29 The fact that cA20 and veltuzumab have virtually the same affinity and off-rate, whereas cA20 has more similar FRs to rituximab than to veltuzumab, emphasizes the more critical role of CDRs than FRs in interacting with CD20. Thus, the significant difference observed in the offrate between veltuzumab/cA20 and rituximab/D101N is apparently due to the single amino acid difference in CDR3-V H , and not to the more extensive differences in the FRs between veltuzumab and rituximab. Accordingly, we believe this is the first single amino-acid change in a CDR that is shown to cause a functional effect, possibly resulting in a more potent antibody.
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As discussed already, these in-vitro off-rate and CDC differences are comparable to the findings with another anti-CD20 MAb, ofatumumab, which was reported to bind to a different epitope than rituximab, 28 and claimed to be therapeutically more active than rituximab in vitro. 4 However, this is not consistent with the relatively high doses chosen for clinical studies, also requiring long infusion times like rituximab, 30, 31 or the lowest dose of 0.5 mg/kg (10 μ g/mouse)
shown to elicit growth inhibition in lymphoma xenografts. 31 Still another recently developed human anti-CD20 MAb, G101, which has properties of a Type-II anti-CD20 MAb, 6 has been shown to be more potent in vitro and in animal models than rituximab, when mice were given repeated doses of 10-30 mg/kg. 6 
16
In conclusion, in-vitro, mouse, monkey, and other human studies indicate that (i)
veltuzumab is active at a fraction of the conventional clinical dose of rituximab or of the minimal therapeutic doses of two other second-generation anti-CD20 MAbs in preclinical models, (ii) survival studies in 3 different lymphoma models showed a significantly higher potency of veltuzumab over rituximab, (iii) the two distinguishing differences in activity vs. rituximab in vitro involve CDC and off-rate functions, and (iv) the lower off-rate appears to be related to a single amino acid mutation at the Kabat-101 residue in the CDR3-V H . This is the first The online version of the article contains a data supplement. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
